| Name | Title | Contact Details |
|---|
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
nContact Surgical is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Neo Dental Laboratory is a Cerritos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NuVasive® is an innovative medical device company focused on developing minimally disruptive surgical products and procedures for the spine. Our mission is to improve the lives of patients who suffer from debilitating back, neck, or leg pain by creating cutting-edge products and procedures that revolutionize spine surgery through focusing on Speed of Innovation®, Absolute Responsiveness®, and Superior Clinical Results. Through innovative technological advancements, NuVasive has successfully progressed major spine surgery to where many patients have experienced extraordinary results—they are often walking the same day of surgery, experiencing less blood loss, spending less time in the hospital, and going back to work within four to six weeks (versus six months). NuVasive is the third largest medical device company in the global spine industry. We feature more than 90 products spanning lumbar, thoracic, and cervical applications, neuromonitoring services, and a biologics portfolio. Our products have been used in hundreds of thousands of spine surgeries. NuVasive had revenues of $811 million in 2015, including sales in over 30 countries, and employs more than 1,600 people globally. Corporate headquarters are in San Diego, California and Amsterdam, the Netherlands serves as international headquarters. The company has additional offices in the U.S. located in the states of Tennessee, Ohio, Maryland, and California. Internationally, NuVasive has additional offices located Puerto Rico, the United Kingdom, Germany, Italy, Australia, Spain, Singapore, and Japan.
Landauer is committed to providing unrivaled radiation monitoring service and to ongoing discovery for improving radiation safety Landauer is the global leader in radiation science and services. We provide tools and support to organizations with potential exposure to ionizing radiation, helping them achieve their radiation safety goals. Our proprietary, state-of-the-art optically stimulated luminescence (OSL) technology enables the most precise measurements possible for occupational radiation monitoring and environmental monitoring and a full range of specialized applications including machine quality assurance and patient radiation monitoring. We back our advanced technology with the most flexible dosimetry programs and best customer service the industry has to offer. While technology continues to advance, one thing is certain with each innovation we must also focus on identifying and mitigating any potential risks related to the benefits. As the first organization to recognize and address radiation risks, and with a sustained history of innovation and dedication unequaled in the industry, LANDAUER is uniquely poised to lead this quest for improved personal and public health and safety across the globe.